Will Microsoft Be a $5 Trillion Stock?
Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…
Buy
54
CSTL Quote, Financials, Valuation and Earnings
Last price:
$19.67
Seasonality move
:
10.13%
Day range:
$19.29 - $19.90
52-week range:
$15.45 - $35.84
Dividend yield:
0%
P/E ratio:
30.24x
P/S ratio:
1.66x
P/B ratio:
1.29x
Volume:
284.1K
Avg. volume:
430.3K
1-year change:
6.33%
Market cap:
$567.6M
Revenue:
$332.1M
EPS (TTM):
-$0.19
Analysts' Opinion
-
Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.89, Castle Biosciences has an estimated upside of 82.55% from its current price of $19.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $19.66.
Fair Value
-
According to the consensus of 8 analysts, Castle Biosciences has 82.55% upside to fair value with a price target of $35.89 per share.
CSTL vs. S&P 500
-
Over the past 5 trading days, Castle Biosciences has underperformed the S&P 500 by -3.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Castle Biosciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Castle Biosciences has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Castle Biosciences reported revenues of $88M.
Earnings Growth
-
Castle Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Castle Biosciences reported earnings per share of -$0.90.
Enterprise value:
302.5M
EV / Invested capital:
--
Price / LTM sales:
1.66x
EV / EBIT:
11.64x
EV / Revenue:
0.87x
PEG ratio (5yr expected):
--
EV / Free cash flow:
7.25x
Price / Operating cash flow:
13.80x
Enterprise value / EBITDA:
7.42x
Gross Profit (TTM):
$284.4M
Return On Assets:
-1.02%
Net Income Margin (TTM):
-1.46%
Return On Equity:
-1.17%
Return On Invested Capital:
-1.15%
Operating Margin:
-31.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $152.2M | $250.7M | $347.1M | $73M | $88M | |
| Gross Profit | $116M | $202M | $284.4M | $59.1M | $71.6M | |
| Operating Income | -$100.7M | -$41.9M | -$13.8M | -$5.5M | -$27.9M | |
| EBITDA | -$62.3M | -$17.9M | $40.8M | $865K | $3.5M | |
| Diluted EPS | -$2.71 | -$1.14 | -$0.19 | -$0.09 | -$0.90 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $426.7M | $336.4M | $271.1M | $295.8M | $349.4M | |
| Total Assets | $437.3M | $444.4M | $426.9M | $458.5M | $501.7M | |
| Current Liabilities | $17.6M | $39.5M | $30.1M | $32M | $37.3M | |
| Total Liabilities | $18.7M | $47.1M | $41.7M | $56M | $61.4M | |
| Total Equity | $418.6M | $397.3M | $385.1M | $402.5M | $440.3M | |
| Total Debt | -- | -- | -- | $10M | $10M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$45.7M | $13M | $65.7M | -$6.8M | -$6M | |
| Cash From Investing | -$149.6M | -$52.5M | -$52.9M | -$19.7M | -$22.4M | |
| Cash From Financing | $1M | $7.6M | -$6.1M | $10.6M | -$1.6M | |
| Free Cash Flow | -$54.2M | -$6.5M | $41.8M | -$16M | -$10.8M | |
CSTL
Sector
Market Cap
$567.6M
$33.5M
Price % of 52-Week High
54.86%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.97%
1-Year Price Total Return
6.33%
-33.61%
Beta (5-Year)
1.103
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$19.94
200-day SMA
Sell
Level
$24.65
Bollinger Bands (100)
Sell
Level
17.08 - 22.38
Chaikin Money Flow
Buy
Level
3.3M
20-day SMA
Buy
Level
$19.52
Relative Strength Index (RSI14)
Buy
Level
55.45
ADX Line
Buy
Level
24.84
Williams %R
Neutral
Level
-39.6517
50-day SMA
Buy
Level
$18.06
MACD (12, 26)
Buy
Level
0.57
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9776)
Buy
CA Score
(Annual)
Level (1.6569)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-5.226)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Stock Forecast FAQ
In the current month, CSTL has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSTL average analyst price target in the past 3 months is $35.89.
-
Where Will Castle Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Castle Biosciences share price will rise to $35.89 per share over the next 12 months.
-
What Do Analysts Say About Castle Biosciences?
Analysts are divided on their view about Castle Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Castle Biosciences is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Castle Biosciences's Price Target?
The price target for Castle Biosciences over the next 1-year time period is forecast to be $35.89 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSTL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Castle Biosciences is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CSTL?
You can purchase shares of Castle Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Castle Biosciences shares.
-
What Is The Castle Biosciences Share Price Today?
Castle Biosciences was last trading at $19.67 per share. This represents the most recent stock quote for Castle Biosciences. Yesterday, Castle Biosciences closed at $19.66 per share.
-
How To Buy Castle Biosciences Stock Online?
In order to purchase Castle Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will C3.ai Stock Be in 1 Year?
C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…
What Is the Ceiling for IONQ Stock?
IonQ (NYSE:IONQ) is a quantum computing startup that, like many…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 12
MiNK Therapeutics [INKT] is up 727.94% over the past day.
Buy
51
NEGG alert for Jul 12
Newegg Commerce [NEGG] is up 74.03% over the past day.
Buy
68
ATRO alert for Jul 12
Astronics [ATRO] is up 16.28% over the past day.
